Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
全球最大的药品公司之一辉瑞公司（NYSE：PFE）即将迎来一个看好的金叉，这是一个重要的技术指标，表明股票有潜在的上涨动能。
Currently, PFE stock is trading at around $30, showing a year-to-date gain of 2.6%, despite being down 16% over the past year.
目前，PFE股票交易价格约为30美元，年初至今已上涨2.6％，尽管过去一年下跌了16％。
Chart created using Benzinga Pro
使用Benzinga Pro创建的图表
The golden cross, where the short-term moving average crosses above the long-term moving average, is viewed by traders as a bullish signal.
金叉是指短期移动平均线上穿长期移动平均线，被交易员视为积极信号。
Chart created using Benzinga Pro
使用Benzinga Pro创建的图表
Pfizer's share price is above its 5, 20, and 50-day exponential moving averages, indicating a strong bullish trend. Specifically, PFE stock is trading above its 8-day simple moving average of $29.04, 20-day SMA of $28.35, and 50-day SMA of $28.37, all suggesting bullish pressure.
辉瑞的股价高于其5、20和50天的指数平均线，表明存在强烈的看好趋势。具体而言，PFE股票的8天简单移动平均线为29.04美元，20天SMA为28.35美元，50天SMA为28.37美元，都说明有看多压力。
Chart created using Benzinga Pro
使用Benzinga Pro创建的图表
Additionally, Pfizer's Moving Average Convergence Divergence (MACD) indicator stands at 0.35, reinforcing the bullish outlook, although the Relative Strength Index (RSI) at 68.96 suggests the stock is nearing overbought territory.
此外，辉瑞的移动平均收敛散度（MACD）指标为0.35，强化了看好的前景，尽管相对强度指数（RSI）为68.96，说明股票即将进入超买区域。
Bollinger Bands further support the bullish sentiment, with the 25-period bands ranging from $26.73 to $29.45, with the stock trading over the upper bullish band.
布林带进一步支持看多情绪，25周期的带子从26.73美元到29.45美元，股票交易在上涨的上限带子上。
Read Also: Pfizer And Roche Advance On Their Weight Loss Drug Journeys
阅读更多：辉瑞和罗氏在减肥药领域取得进展
Pfizer Catalysts – Comirnaty, Paxlovid, Seagen's Oncology Portfolio
辉瑞的催化剂--Comirnaty、Paxlovid、Seagen的肿瘤学组合
Looking ahead, Pfizer is anticipated to potentially exceed its financial guidance, driven by higher utilization of its products such as Comirnaty and Paxlovid, and strong performance from its newly acquired oncology portfolio from Seagen.
展望未来，辉瑞有望可能超越其财务指导，由于其产品，如Comirnaty和Paxlovid的高利用率，以及从Seagen收购的新获得的肿瘤组合表现强劲。
Analysts forecast up to 30% growth in its oncology franchise and vaccine sales, contributing to Pfizer's ambitious goal of adding $25 billion in risk-adjusted revenue by 2030.
分析师预测其肿瘤治疗领域和疫苗销售增长高达30％，有助于辉瑞的宏伟目标，即到2030年增加250亿美元的风险调整收入。
However, challenges remain. Demand for Pfizer's COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.
然而，仍然存在挑战。辉瑞COVID-19产品和肿瘤药物的需求可能低于预期，且与主要产品销售、价格压力和管道开发相关的风险仍然存在。
Despite these concerns, the upcoming golden cross and recent bullish signals suggest Pfizer stock may be poised for further gains.
尽管存在这些担忧，即将到来的金叉和最近的看多信号表明辉瑞股票可能会进一步上涨。
As Pfizer prepares to report its Q2 earnings, all eyes will be on whether these bullish indicators translate into sustained growth for the pharmaceutical giant.
随着辉瑞准备报告其第二季度业绩，所有人都将关注这些看多指标是否能够转化为制药巨头持续增长。
- Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
- 辉瑞，思科，艾奇资本和更多： CNBC的"最终交易"
Photo: Shutterstock
Photo: shutterstock